The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

被引：2
|
作者：
Addeo, Raffaele [1 ]
Caraglia, Michele [2 ]
机构：
[1] S Giovanni di Dio Hosp, Oncol Unit, ASL Napoli 2, I-80027 Naples, Italy
[2] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2011年 / 11卷 / 02期
关键词：
blood-brain barrier; brain metastasis; breast cancer; chemotherapy; lapatinib; sunitinib; tyrosine kinase inhibitor; whole-brain radiotherapy; NERVOUS-SYSTEM METASTASES; PHASE-II TRIAL; TEMOZOLOMIDE; CARCINOMA; RADIOTHERAPY; CAPECITABINE; BEVACIZUMAB; COMBINATION; THERAPY; DISEASE;
D O I：
10.1586/ERA.10.190
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：139 / 142
页数：4
相关论文
共 50 条
  • [31] Opportunities for Rapid Monitoring of New Cancer Treatments - Tyrosine Kinase Inhibitors in the Sentinel Database
    Wagner, Anita K.
    Haug, Nicole
    Hou, Laura
    Welch, Emily C.
    Lu, Christine Y.
    Toh, Darren
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 118 - 118
  • [32] A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer
    Larsen, Pia Bukmann
    Kumler, Iben
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2013, 39 (07) : 720 - 727
  • [33] Treatment and prognosis of brain metastases from breast cancer
    Ogawa, Kazuhiko
    Yoshii, Yoshihiko
    Nishimaki, Tadashi
    Tamaki, Nobumitsu
    Miyaguni, Takao
    Tsuchida, Yukihiro
    Kamada, Yoshihiko
    Toita, Takafumi
    Kakinohana, Yasumasa
    Tamaki, Wakana
    Iraha, Shiro
    Adachi, Genki
    Hyodo, Akio
    Murayama, Sadayuki
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 231 - 238
  • [34] Treatment and prognosis of brain metastases from breast cancer
    Kazuhiko Ogawa
    Yoshihiko Yoshii
    Tadashi Nishimaki
    Nobumitsu Tamaki
    Takao Miyaguni
    Yukihiro Tsuchida
    Yoshihiko Kamada
    Takafumi Toita
    Yasumasa Kakinohana
    Wakana Tamaki
    Shiro Iraha
    Genki Adachi
    Akio Hyodo
    Sadayuki Murayama
    Journal of Neuro-Oncology, 2008, 86 : 231 - 238
  • [35] Systemic treatment of brain metastases from breast cancer
    Taillibert, S.
    Conforti, R.
    Bonneterre, J.
    Bachelot, T.
    Le Rhun, E.
    Bernard-Marty, C.
    CANCER RADIOTHERAPIE, 2015, 19 (01): : 36 - 42
  • [36] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
    Martinello, Rossella
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Nuzzo, Annamaria
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
  • [37] Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?
    Kleespies, Axel
    Jauch, Karl-Walter
    Bruns, Christiane J.
    DRUG RESISTANCE UPDATES, 2006, 9 (1-2) : 1 - 18
  • [38] Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
    Turco, Fabio
    Tucci, Marcello
    Di Stefano, Rosario Francesco
    Samuelly, Alessandro
    Bungaro, Maristella
    Bollito, Enrico
    Scagliotti, Giorgio Vittorio
    Buttigliero, Consuelo
    TUMORI JOURNAL, 2021, 107 (06): : NP149 - NP154
  • [39] New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
    Nancy U Lin
    Eric P Winer
    Breast Cancer Research, 6
  • [40] Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
    Ocana, Alberto
    Serrano, Rosario
    Calero, Raul
    Pandiella, Atanasio
    CURRENT DRUG TARGETS, 2009, 10 (06) : 575 - 576
12345